Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH

被引：79

作者：

Cariello, Marica ^{[1
]}

Piccinin, Elena ^{[2
]}

Moschetta, Antonio ^{[1
,3
,4
]}

机构：

[1] Univ Bari Aldo Moro, Dept Interdisciplinary Med, Bari, Italy

[2] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

[3] Natl Inst Biostruct & Biosyst INBB, Rome, Italy

[4] Ist Tumori Giovanni Paolo II, Sci Inst Res Hospitalizat & Healthcare IRCCS, Bari, Italy

来源：

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 11卷 / 05期

关键词：

Nonalcoholic Steatohepatitis (NASH); Nuclear Receptors; Peroxisome Proliferator Activated Receptors (PPARs); Farnesoid X Receptor (FXR); Liver X Receptor (LXR); NONALCOHOLIC FATTY LIVER; FARNESOID-X-RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTORS; INDUCED HEPATIC STEATOSIS; LIFE-STYLE MODIFICATION; ACID TRANSPORT PROTEIN; GENE-EXPRESSION; BILE-ACIDS; DELTA AGONIST; NUTRITIONAL FIBROSIS;

D O I：

10.1016/j.jcmgh.2021.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Nonalcoholic fatty liver disease comprises a wide spectrum of liver injuries from simple steatosis to steatohepatitis and cirrhosis. Nonalcoholic steatohepatitis (NASH) is defined when liver steatosis is associated with inflammation, hepatocyte damage, and fibrosis. A genetic predisposition and environmental insults (ie, dietary habits, obesity) are putatively responsible for NASH progression. Here, we present the impact of the lipid-sensing nuclear receptors in the pathogenesis and treatment of NASH. In detail, we discuss the pros and cons of the putative transcriptional action of the fatty acid sensors (peroxisome proliferator-activated receptors), the bile acid sensor (farnesoid X receptor), and the oxysterol sensor (liver X receptors) in the pathogenesis and bona fide treatment of NASH.

引用

页码：1519 / 1539

页数：21

共 208 条

[1] Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions [J].

Adolph, Timon E. ;

Grander, Christoph ;

Grabherr, Felix ;

Tilg, Herbert .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)

[2] Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis [J].

Adorini, Luciano ;

Pruzanski, Mark ;

Shapiro, David .

DRUG DISCOVERY TODAY, 2012, 17 (17-18) :988-997

[3] Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease [J].

Ahn, Sang Bong ;

Jang, Kiseok ;

Jun, Dae Won ;

Lee, Byung Hoon ;

Shin, Kye Jung .

DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (12) :2975-2982

[4] Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration [J].

Alvarez-Sola, Gloria ;

Uriarte, Iker ;

Ujue Latasa, M. ;

Fernandez-Barrena, Maite G. ;

Urtasun, Raquel ;

Elizalde, Maria ;

Barcena-Varela, Marina ;

Jimenez, Maddalen ;

Chang, Haisul C. ;

Barbero, Roberto ;

Catalan, Victoria ;

Rodriguez, Amaia ;

Fruhbeck, Gema ;

Gallego-Escuredo, Jose M. ;

Gavalda-Navarr, Aleix ;

Villarroya, Francesc ;

Rodriguez-Ortigosa, Carlos M. ;

Corrales, Fernando J. ;

Prieto, Jesus ;

Berraondo, Pedro ;

Berasain, Carmen ;

Avila, Matias A. .

GUT, 2017, 66 (10) :1818-1828

[5] Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor α, retinoid X receptor, and liver X receptor in mouse liver [J].

Anderson, SP ;

Dunn, C ;

Laughter, A ;

Yoon, L ;

Swanson, C ;

Stulnig, TM ;

Steffensen, KR ;

Chandraratna, RAS ;

Gustafsson, JÅ ;

Corton, JC .

MOLECULAR PHARMACOLOGY, 2004, 66 (06) :1440-1452

[6] Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα) [J].

Aoyama, T ;

Peters, JM ;

Iritani, N ;

Nakajima, T ;

Furihata, K ;

Hashimoto, T ;

Gonzalez, FJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (10) :5678-5684

[7] Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension [J].

Avouac, Jerome ;

Konstantinova, Irena ;

Guignabert, Christophe ;

Pezet, Sonia ;

Sadoine, Jeremy ;

Guilbert, Thomas ;

Cauvet, Anne ;

Tu, Ly ;

Luccarini, Jean-Michel ;

Junien, Jean-Louis ;

Broqua, Pierre ;

Allanore, Yannick .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (11) :1931-1940

[8] Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace [J].

Baffy, Gyoergy ;

Brunt, Elizabeth M. ;

Caldwell, Stephen H. .

JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1384-1391

[9] Kupffer cells in non-alcoholic fatty liver disease: The emerging view [J].

Baffy, Gyoergy .

JOURNAL OF HEPATOLOGY, 2009, 51 (01) :212-223

[10] MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin [J].

Bays, Harold E. ;

Schwartz, Sherwyn ;

Littlejohn, Thomas, III ;

Kerzner, Boris ;

Krauss, Ronald M. ;

Karpf, David B. ;

Choi, Yun-Jung ;

Wang, Xueyan ;

Naim, Sue ;

Roberts, Brian K. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) :2889-2897

← 1 2 3 4 5 6 7 8 9 10 →